Table 1.
Baseline characteristics
| Baseline characteristics
|
ETDRS BCVA
|
OCT measurements, sSRF/mSRF (μm)
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient ID | Gender | Age (years) | Eye | Risk factors | Duration of CSC before ZivA-PDT | Baseline | At 6 months | Baseline | At 6 months |
| 1 | M | 58 | OD | CS | >4 years | 40 | 40 | 193/262 | 0/0 |
| 2 | F | 52 | OD | HT | 9 months | 75 | 85 | 144/149 | 0/48 |
| 3 | M | 42 | OD | S | 9 months | 80 | 85 | 344/366 | 0/5 |
| 4 | M | 42 | OS | 1 year* | 85 | MD | 37/107 | MD | |
| 5 | M | 68 | OD | CS, HT | 4 months | 60 | 80 | 311/327 | 0/0 |
| 6 | M | 53 | OD | HT | 8 months | 75 | MD | 234/324 | MD |
| 7 | M | 40 | OD | S | 1.5 years | 70 | 35 | 115/233 | 84/144 |
| 8 | M | 69 | OD | 6 years | 55 | 70 | 282/282 | 112/112 | |
| 9 | M | 46 | OS | CS, HT | 5.5 years | 85 | 85 | 200/200 | 0/68 |
| 10 | M | 53 | OS | CS | 1.5 years | 65 | 85 | 162/212 | 0/178 |
| 11 | M | 47 | OD | 6 months | 75 | MD | 301/301 | MD | |
| 12 | F | 67 | OD | CS | >3 years | 5 | MD | 184/185 | MD |
| 13 | M | 48 | OS | >4.5 years | 65 | 70 | 199/231 | 231/240 | |
| 14 | M | 51 | OD | 3.5 years | 70 | 70 | 316/322 | 106/107 | |
| 15 | M | 64 | OS | HT | >4 years | 75 | 75 | 251/252 | 177/177 |
| 16 | M | 46 | OS | HT | 1.5 years | 65 | 75 | 75/79 | 14/14 |
| 17 | M | 40 | OS | >2.5 years | 85 | 85 | 100/100 | 0/117 | |
| 18 | F | 61 | OD | >1 years | 80 | 75 | 250/250 | 30/39 | |
| Mean/summary | 15 M/3 F | 52.6 | 11 OD/7 OS | 6× HT/5× CS 2× S | >28.5 months | 67.2 | 75.0 | 205/232 | 54/78 |
| ±SD | 9.8 | >20.0 months | 18.8 | 15.4 | 86/81 | 74/72 | |||
Note:
*
Bilateral CSC, diagnosis for 1 year, but symptoms of the treated eye for just 1 month.
Abbreviations: BCVA, best corrected visual acuity; CS, corticosteroids; CSC, central serous chorioretinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study; F, female; HT, hypertension; M, male; MD, missing data; mSRF, maximum subretinal fluid; OCT, optical coherence tomography; OD, right eye; OS, left eye; PDT, photodynamic therapy; S, stress; SD, standard deviation; sSRF, subfoveal subretinal fluid; ZivA, ziv-aflibercept and aflibercept.